Objectives: To detail the US multi-institutional experience with Occlutech© (Occlutech International AB, Helsingborg, Sweden) atrial flow regulator (AFR) in children and adults acquired or congenital heart disease. Background: The creation of a long-term communication is desirable several cardiovascular disease phenotypes, most notably pulmonary arterial hypertension, disorders increased left v...